



The Nifty ended 0.37% up at 14,873.80. It opened on a positive note, however, vigorous sell off in the later half led to a Doji candle on the daily chart. Candle pattern suggests indecision amongst traders likely to persist. Failing to sustain above 14,950, day's high was 14,984.15, is an indication of range-bound oscillation in the price band of 15,000-14,750. Lower support is placed around 14,650 levels.

On the Nifty hourly chart; direction of the leading indicators pointing towards critical MA band centric oscillation in the price band of 14,750-15,000.

Nifty patterns on multiple time frames suggest; 14,950-15,000 is the critical resistance zone ahead. Failing to breakout may take down the benchmark index back towards 14,750 levels. Staying cautious on rise is advised.

Nifty Crucial Supports & Resistances-

Supports- 14750, 14650 Resistances- 14950, 15000

Open Positional Calls-

T+5 Positional Buy-
|Cash Segment| REC @ 131-130,
TGT- 138, Closing SL- 126

T+3 Positional Buy-
|Cash Segment| SBIN @ 352-350,
TGT- 370, Closing SL- 340

T+5 Positional Buy-
|Cash Segment| CADILA @ 458-455,
TGT- 478, Closing SL- 445

T+5 Positional Sell-
|Futures Segment| SAIL Fut @ 91-
92, TGT- 82, SL- above 97

Key Contents	Page No.
Domestic News	4

Nifty Intraday Chart



Market in Retrospect

Indian equities gained for the third straight day on Thursday. However, volatility related to the weekly options expiry dragged the indices lower from their respective day's high.

The NIFTY index ended 0.37% higher at 14,874. The broader markets represented by the NIFTY 500 Index ended 0.48% higher, ending at 12,542. Among the sectorial indices, NIFTY Metal was the top gainer, gaining by 3.92%, followed by NIFTY IT, gaining by 1.18% higher. NIFTY PSU Bank was the top loser, losing by 0.85%.

JSW Steel was the top gainer, gaining by 9.21%, followed by Tata Steel and Shree Cement which gained by 4.98% & 4.47% respectively. Indusind Bank was the top loser, losing by 1.13%, followed by Sun Pharma and SBI Life Insurance, which fell by 1.09% & 1.09% respectively.

The Advance: Decline ratio stood at 1233:668

Market Turnover (In Crore) 08-04-2021

Name	Last	Previous
NSE Cash	*NA	72350.05
NSE F&O	8504305.48	4386299.24
BSE Cash	6,430.80	4,260.60
BSE F&O	*NA	129.23

FII Derivatives Flow (In Crore) 07-04-2021*

Instrument	Purchase	Sale	Net
Index Future	6148.46	5386.51	761.95
Index Option	536185.43	536668.65	483.22
Stock Future	12405.67	12106.50	299.17
Stock Option	9646.64	9700.59	53.95

Institutional Flow (In Crore) 08-04-2021

Institution	Purchase	Sale	Net
FII	8752.01	8641.16	110.85
DII	4854.39	4301.61	552.78

*Data not updated till 5.50pm

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
JSW Steel	9.21	31.09	72006147	23928260
Tata Steel	4.98	13.12	53063056	26670960
Shree Cement	4.47	7.19	148094	70673
Titan	3.78	0.85	2085919	1628939
Hindalco Industries	3.69	11.73	28768469	14903920

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
HDFC Bank	1.00	4.07	8806796	12270880
ONGC	1.00	1.42	26105970	18450630
SBI Life Insurance	1.09	3.14	1342782	1685074
Sun Pharmaceutical	1.09	2.75	3222479	5771956
Indusind Bank	1.13	2.05	3946239	7250023

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	49746.21	84.45	0.17	0.48	1.38	1.98	66.41
Nifty	14873.80	54.75	0.37	1.25	0.55	3.67	70.01
BSE M Cap	20777.81	124.52	0.60	2.96	0.62	8.56	89.30
BSE S Cap	21449.57	156.17	0.73	3.88	1.82	13.44	114.93
Nifty MC 100	24462.40	129.10	0.53	3.25	1.30	10.22	101.44
BSE Auto	22445.53	56.31	0.25	0.87	5.32	2.03	95.83
BSE Capgoods	21236.50	104.83	0.50	0.67	4.66	6.61	92.51
BSE FMCG	12945.90	60.80	0.47	0.55	5.56	2.78	19.42
BSE Metal	16338.00	694.66	4.44	13.85	16.21	29.07	178.65
BSE Oil&Gas	14990.91	41.12	0.28	1.15	8.32	1.76	38.98
BSE Healthcare	22210.23	81.08	0.37	4.14	4.43	0.34	58.37
BSE Power	2514.00	26.36	1.04	1.57	0.66	17.55	80.27
BSE Realty	2658.36	24.20	0.92	0.45	5.74	2.87	92.54
BSE ConsDur	33092.68	833.73	2.58	0.81	1.12	6.10	69.95
BSE Bank	37075.25	227.09	0.61	1.26	6.64	1.14	70.87
BSE IT	27922.24	266.74	0.96	5.20	8.78	8.08	122.81

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.65	0.03	1.68	1.45	3.46	47.56	113.12
UK	0.77	0.00	0.13	2.89	2.39	168.06	101.04
Brazil	4.20	0.01	0.17	1.96	0.94	22.38	7.00
Japan	0.10	0.00	1.01	13.27	20.33	180.00	308.33
Australia	1.74	0.01	0.51	5.43	1.69	54.76	89.65
India	6.03	0.05	0.86	2.19	3.01	2.66	6.37
Switzerland	0.30	0.02	6.76	2.28	22.95	38.27	22.45
Germany	0.33	0.01	2.16	0.92	19.50	36.22	8.17

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.58	0.02	0.02	1.97	1.78	1.79	2.31
USD Index	92.40	0.06	0.06	0.90	0.09	2.55	7.71
YUAN	6.55	0.01	0.11	0.24	0.36	1.14	7.88
GBP	1.37	0.00	0.07	0.63	0.56	1.31	11.01
EUR	1.19	0.00	0.03	0.74	0.14	2.90	9.27
YEN	109.53	0.32	0.29	1.00	0.58	5.10	0.64

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2127.00	35.00	1.67	1.62	14.79	32.44	250.41
Baltic Dirty	675.00	10.00	1.46	8.41	0.45	29.81	36.97
SG Dubai HY	0.70	0.56	400.00	391.67	84.21	15.66	270.73

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	33446.26	16.02	0.05	1.15	5.17	7.55	42.73
Nasdaq	13688.84	9.54	0.07	4.93	8.56	3.69	69.19
S&P 500	4079.95	6.01	0.15	3.07	6.77	6.67	48.36
FTSE100	6910.83	25.01	0.36	2.04	2.85	0.54	21.71
CAC40	6158.88	28.22	0.46	1.16	4.33	7.92	38.63
DAX	15169.84	7.79	0.05	1.07	5.48	7.96	46.80
Mexico IPC	47897.84	87.59	0.18	0.32	1.75	2.50	38.56
Brazil Bovespa	117623.6	124.70	0.11	0.66	6.34	5.96	49.60
Russian RTS	1429.07	0.37	0.03	1.89	1.21	2.50	28.29
Japan Nikkei	29708.98	21.81	0.07	1.09	3.36	5.58	53.51
Hang Seng	29008.07	333.27	1.16	2.36	1.64	4.05	21.02
Taiwan Index	16926.44	111.08	0.66	2.24	6.99	9.46	66.97
Shanghai Comp	3482.56	2.93	0.08	1.18	1.79	2.45	23.70
KOSPI	3143.26	5.85	0.19	1.81	4.91	0.28	73.94
Malaysia KLCI	1602.40	1.81	0.11	1.25	0.58	1.89	17.70
Jakarta Comp	6071.72	35.11	0.58	1.44	2.83	2.97	31.23
Philippine SE	6545.17	106.54	1.60	0.01	3.13	10.22	18.77
Thai Exch	1558.83	2.27	0.15	1.79	0.98	1.46	29.28

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	59.28	0.44	0.74	3.45	8.79	13.57	136.47
BRENT Crude	62.77	0.33	0.52	0.14	7.19	13.68	55.83
Natural Gas	2.49	0.03	1.03	5.49	7.56	6.94	2.97

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1746.30	8.44	0.49	0.97	3.72	5.56	6.08
Silver(\$/Ounce)	25.33	0.19	0.74	1.46	0.83	0.35	69.35
Aluminium	2240.25	9.25	0.41	0.09	2.87	10.45	55.58
Copper	8919.00	134.75	1.49	0.60	0.07	9.21	77.71
Zinc	2812.00	6.20	0.22	0.13	2.12	1.80	46.80
Lead	1971.71	25.71	1.32	2.10	0.59	2.12	14.30

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	127.65	0.90	0.71	3.36	1.16	1.51	1.55
Cotton	80.38	0.88	1.11	0.62	8.99	0.21	40.01
Sugar	15.20	0.06	0.40	2.91	6.17	2.91	34.28
Wheat	623.00	6.75	1.10	1.96	3.63	2.77	10.07
Soybean	1407.50	1.25	0.09	0.39	1.83	2.64	63.95

JSW Steel's crude steel production up by 6% to 4.19 mt in Q4 of FY 21

JSW Steel reported a 6% growth in the crude steel production of 4.19 million tonnes in the last quarter of the financial year 2021, as against 3.97 million tonnes a year ago. The company's average capacity utilisation improved from 91% for the third quarter to 93% in Q4 of FY 21. However, the capacity utilisation during the month of March 2021 was 96%. During the quarter under review, the flat steel production went up by 4% year-on-year to 2.99 mt and long steel production went up by 11%. On a quarter on quarter basis, flat steel production remained flat whereas long steel registered a growth of 13% indicating a rise in infrastructure and construction demand. For the financial year FY 21, JSW Steel's production fell short by 6% to 15.08 million tonnes owing to the stringent pandemic-led lockdown during the first half of the financial year. In FY20, the company registered a crude steel production growth of 16.06 million tonnes.

PV retail sales up 28 pc, two-wheeler registrations drop 35 pc in March

Passenger vehicle (PV) retail sales in March witnessed a year-on-year growth of 28.39 per cent to 2,79,745 units, as compared to year-ago period which saw disruptions in the market due to COVID-19 led lockdown. FADA which collected vehicle registration data from 1,277 out of the 1,482 regional transport offices (RTOs), PV sales stood at 2,17,879 units in March 2020. Two-wheeler sales, however, declined 35.26 per cent to 11,95,445 units last month, as compared to 18,46,613 units in March 2020. Commercial vehicle sales also fell 42.2 per cent to 67,372 units against 1,16,559 units a year ago. Similarly, three-wheeler sales dropped 50.72 per cent to 38,034 units last month from 77,173 units in the year-ago period. Tractor sales, however, grew by 29.21 per cent to 69,082 units last month, against 53,463 units in the same month last year. Total registrations across categories declined by 28.64 per cent to 16,49,678 units last month compared to 23,11,687 units in the year-ago period

India to resume buying oil from Iran once US sanctions ease

India will look to resume buying crude oil from Iran the moment US sanctions are eased, helping it diversify its import basket, a senior government official said. India stopped importing oil from Iran in mid-2019 following sanctions on the Persian Gulf nation by the Trump administration. The US and other world powers are meeting in Vienna to revive the Iran nuclear deal. Once the sanctions are lifted, we can look to resume oil imports from Iran. Indian refiners have begun preparatory work and can swiftly enter into contracts once the sanctions are lifted. Iranian oil coming into the market will not just cool prices but also help India diversify its import basket. In 2020-21, Iraq was India's biggest oil supplier, followed by Saudi Arabia and the UAE. Nigeria was fourth-largest supplier and the US was the fifth.

Zydus Cadila gets USFDA nod for cancer and high blood pressure, treatment drug

Zydus Cadila has received final approval from the US health regulator to market Ibrutinib Capsules, used to treat certain cancers. The company has also received nod to market Macitentan tablets, used to treat high blood pressure. Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Ibrutinib Capsules in the strengths of 70 mg and 140 mg. Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia. The company is eligible for 180 days of generic drug exclusivity for Ibrutinib Capsules, 70 mg and for Ibrutinib Capsules, 140 mg. The 70 mg capsule has brand sales of USD 32.5 million, while the 140 mg dose has brand sales of USD 745.9 million. The group now has 314 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Rama Phosphates Ltd	Cash dividend of INR1 effective 09-04-2021
Roto Pumps Ltd	Cash dividend of INR1.40 effective 09-04-2021
Pritika Auto Industries Ltd	5 for 1 stock split effective 09-04-2021
Ambuja Cements Ltd	Corporate meeting effective 09-04-2021
United Breweries Ltd	Corporate meeting effective 09-04-2021
SK International Export Ltd	Corporate meeting effective 09-04-2021
BCPL Railway Infrastructure Ltd	Corporate meeting effective 09-04-2021
Newtime Infrastructure Ltd	Corporate meeting effective 09-04-2021

Domestic Events

- India Foreign Exchange Reserve for April 02, 2021.

Global Events

- China Inflation for March 2021.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com